Home LiteratureArticle Details
PMID: 29628498 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.

Cellular & molecular immunology ·Vol. 16 ·No. 1 ·2019-00-00 ·Pages 6-18

Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L

Abstract

Evidence indicates that lung cancer development is a complex process that involves interactions between tumor cells, stromal fibroblasts, and immune cells. Tumor-infiltrating immune cells play a significant role in the promotion or inhibition of tumor growth. As an integral component of the tumor microenvironment, tumor-infiltrating B lymphocytes (TIBs) exist in all stages of cancer and play important roles in shaping tumor development. Here, we review recent clinical and preclinical studies that outline the role of TIBs in lung cancer development, assess their prognostic significance, and explore the potential benefit of B cell-based immunotherapy for lung cancer treatment.

Keywords
B cells Bregs immunotherapy lung cancer tumor-infiltrating B cells
MeSH Terms
B-Lymphocytes/immunology B-Lymphocytes, Regulatory/immunology Humans Immunity Immunotherapy Lung Neoplasms/immunology,therapy Lymphocytes, Tumor-Infiltrating/immunology
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Wang Si-Si ORCID
Department of Translational Medicine, The First Hospital of Jilin University, Changchun, 130061, China.
Liu Wei
Department of Translational Medicine, The First Hospital of Jilin University, Changchun, 130061, China. davidliuw@hotmail.com. | Department of Thoracic surgery, The First Hospital of Jilin University, Changchun, 130021, China. davidliuw@hotmail.com.
Ly Dalam ORCID
Toronto General Hospital Research Institute, University Health Network, Toronto, ON, M5G 1L7, Canada. | Departments of Laboratory Medicine and Pathobiology, Immunology, University of Toronto, Toronto, ON, M5G 1L7, Canada.
Xu Hao
Department of Translational Medicine, The First Hospital of Jilin University, Changchun, 130061, China.
Qu Limei
Department of Pathology, The First Hospital of Jilin University, Changchun, 130021, China.
Zhang Li
Toronto General Hospital Research Institute, University Health Network, Toronto, ON, M5G 1L7, Canada. lzhang@uhnresearch.ca. | Departments of Laboratory Medicine and Pathobiology, Immunology, University of Toronto, Toronto, ON, M5G 1L7, Canada. lzhang@uhnresearch.ca.
References (97)
97 references, click to expand
  1. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
    J Clin Oncol. 2008 Sep 20;26(27):4410-7 PMID: 18802153
  2. RETRACTED: Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in Non Small Cell Lung Carcinoma patients.
    Hum Immunol. 2016 Jan;77(1):84-89 PMID: 26527508
  3. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature.
    J Immunol. 2009 Feb 15;182(4):2113-23 PMID: 19201864
  4. Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α.
    J Immunol. 2013 Mar 15;190(6):2575-84 PMID: 23408836
  5. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.
    Cancer Immunol Immunother. 2008 Jan;57(1):85-95 PMID: 17605009
  6. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    J Immunol. 2013 Jul 1;191(1):217-27 PMID: 23698748
  7. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
    Cancer Cell. 2005 May;7(5):411-23 PMID: 15894262
  8. Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses.
    Cancer Immun. 2008 Feb 19;8:4 PMID: 18281925
  9. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.
    Immunity. 2001 Feb;14(2):111-21 PMID: 11239444
  10. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
    Nat Rev Cancer. 2016 May;16(5):275-87 PMID: 27079802
  11. Immune regulatory function of B cells.
    Annu Rev Immunol. 2012;30:221-41 PMID: 22224776
  12. Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator.
    Cancer Immunol Res. 2016 Mar;4(3):234-47 PMID: 26787825
  13. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation.
    J Immunol. 2004 Jul 15;173(2):892-9 PMID: 15240676
  14. Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery.
    Cancer Immunol Immunother. 2016 Feb;65(2):171-80 PMID: 26739486
  15. The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution.
    Elife. 2015 Nov 13;4: PMID: 26565418
  16. Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients.
    Cancer Immunol Res. 2017 Oct;5(10):898-907 PMID: 28848053
  17. B regulatory cells in cancer.
    Trends Immunol. 2013 Apr;34(4):169-73 PMID: 23206438
  18. Regulatory B cells in anti-tumor immunity.
    Int Immunol. 2015 Oct;27(10):521-30 PMID: 25999597
  19. B cell regulation of the anti-tumor response and role in carcinogenesis.
    J Immunother Cancer. 2016 Jul 19;4:40 PMID: 27437104
  20. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.
    Mol Cancer. 2016 Oct 27;15(1):67 PMID: 27784305
  21. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.
    J Immunol. 2013 Oct 15;191(8):4141-51 PMID: 24043896
  22. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer.
    Cancer Res. 2011 Oct 15;71(20):6391-9 PMID: 21900403
  23. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    J Immunol. 1998 Dec 15;161(12):6977-84 PMID: 9862733
  24. Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma.
    Clin Cancer Res. 2013 Nov 1;19(21):5994-6005 PMID: 24056784
  25. B cell regulation in cancer and anti-tumor immunity.
    Cell Mol Immunol. 2017 Aug;14(8):662-674 PMID: 28626234
  26. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Transl Res. 2017 Sep;187:1-10 PMID: 28502785
  27. Comprehensive molecular profiling of lung adenocarcinoma.
    Nature. 2014 Jul 31;511(7511):543-50 PMID: 25079552
  28. B cell-regulated immune responses in tumor models and cancer patients.
    Oncoimmunology. 2013 Jul 1;2(7):e25443 PMID: 24073382
  29. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer.
    Hum Pathol. 2013 Aug;44(8):1569-76 PMID: 23465276
  30. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.
    Am J Respir Crit Care Med. 2015 Feb 15;191(4):377-90 PMID: 25369536
  31. Tertiary lymphoid structures in cancer and beyond.
    Trends Immunol. 2014 Nov;35(11):571-80 PMID: 25443495
  32. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.
    Am J Respir Crit Care Med. 2011 May 15;183(10):1369-79 PMID: 21278302
  33. Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma.
    BMC Med Genomics. 2014 Jun 10;7:33 PMID: 24916928
  34. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.
    Eur J Immunol. 2015 Apr;45(4):999-1009 PMID: 25545618
  35. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.
    APMIS. 2010 May;118(5):371-82 PMID: 20477813
  36. Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer.
    J Transl Med. 2014 Nov 11;12:304 PMID: 25381811
  37. The prognostic landscape of genes and infiltrating immune cells across human cancers.
    Nat Med. 2015 Aug;21(8):938-945 PMID: 26193342
  38. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
    Nature. 2015 May 7;521(7550):94-8 PMID: 25924065
  39. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
    Ann Oncol. 2016 Nov;27(11):2117-2123 PMID: 27502728
  40. Influence of drug molecules on regulatory B cells.
    Clin Immunol. 2017 Nov;184:1-10 PMID: 28461109
  41. STATs in cancer inflammation and immunity: a leading role for STAT3.
    Nat Rev Cancer. 2009 Nov;9(11):798-809 PMID: 19851315
  42. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
    J Natl Cancer Inst. 2016 Jun 22;108(11): PMID: 27335052
  43. Ectopic lymphoid-like structures in infection, cancer and autoimmunity.
    Nat Rev Immunol. 2014 Jul;14(7):447-62 PMID: 24948366
  44. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy.
    Lung Cancer. 2013 May;80(2):209-15 PMID: 23384671
  45. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.
    JCI Insight. 2016 Sep 8;1(14):e89014 PMID: 27699239
  46. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L.
    Cancer Res. 2013 Apr 1;73(7):2127-38 PMID: 23365136
  47. Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung.
    Respir Res. 2009 Oct 22;10:97 PMID: 19845971
  48. A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality.
    Oncoimmunology. 2015 Jun 1;4(12):e1051922 PMID: 26587322
  49. FcRgamma activation regulates inflammation-associated squamous carcinogenesis.
    Cancer Cell. 2010 Feb 17;17(2):121-34 PMID: 20138013
  50. Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma.
    PLoS One. 2015 Sep 28;10(9):e0139073 PMID: 26413839
  51. Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma.
    Lung Cancer. 1999 Nov;26(2):73-83 PMID: 10568678
  52. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma.
    Clin Cancer Res. 2000 May;6(5):1875-81 PMID: 10815910
  53. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.
    Clin Cancer Res. 2012 May 1;18(9):2695-703 PMID: 22351685
  54. Immunization of fucose-containing polysaccharides from Reishi mushroom induces antibodies to tumor-associated Globo H-series epitopes.
    Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13809-14 PMID: 23908400
  55. Lung Cancer Statistics.
    Adv Exp Med Biol. 2016;893:1-19 PMID: 26667336
  56. Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner.
    Cell Mol Immunol. 2017 Jan 02;: PMID: 28042143
  57. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Clin Cancer Res. 2008 Aug 15;14(16):5220-7 PMID: 18698040
  58. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2016 Jun;11(6):789-800 PMID: 26845192
  59. CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles.
    Mucosal Immunol. 2009 Nov;2(6):486-94 PMID: 19741597
  60. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.
    Clin Transl Oncol. 2015 Apr;17(4):330-8 PMID: 25301404
  61. Objective measurement and clinical significance of TILs in non-small cell lung cancer.
    J Natl Cancer Inst. 2015 Feb 03;107(3): PMID: 25650315
  62. Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer.
    Cancer Res. 2002 Mar 15;62(6):1751-6 PMID: 11912150
  63. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression.
    J Lab Clin Med. 2002 Nov;140(5):320-8 PMID: 12434133
  64. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells.
    Cancer Res. 2013 Apr 15;73(8):2468-79 PMID: 23384943
  65. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer.
    PLoS One. 2013;8(1):e54029 PMID: 23326565
  66. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.
    Cancer Res. 2011 May 15;71(10):3505-15 PMID: 21444674
  67. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
    Cancer Cell. 2014 Jun 16;25(6):809-821 PMID: 24909985
  68. CXCL13 production in B cells via Toll-like receptor/lymphotoxin receptor signaling is involved in lymphoid neogenesis in chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2013 Jun 1;187(11):1194-202 PMID: 23525932
  69. Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer.
    Oncotarget. 2016 Nov 1;7(44):71608-71619 PMID: 27689405
  70. Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles.
    J Immunol. 2005 May 1;174(9):5720-8 PMID: 15843574
  71. B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment.
    Oncoimmunology. 2017 Mar 3;6(4):e1294296 PMID: 28507802
  72. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
    J Thorac Oncol. 2011 Oct;6(10):1687-90 PMID: 21642860
  73. Protective Effects of Total Glucosides of Paeony on N-nitrosodiethylamine-induced Hepatocellular Carcinoma in Rats via Down-regulation of Regulatory B Cells.
    Immunol Invest. 2015;44(6):521-35 PMID: 26207789
  74. Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?
    Cancer Immunol Immunother. 2014 Jul;63(7):643-62 PMID: 24695950
  75. B cells promote tumor progression via STAT3 regulated-angiogenesis.
    PLoS One. 2013 May 29;8(5):e64159 PMID: 23734190
  76. Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells.
    Cancer Lett. 2015 Aug 10;364(2):118-24 PMID: 25979229
  77. Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.
    F1000Res. 2016 Jan 08;5:38 PMID: 27081474
  78. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer.
    Cancer Lett. 2013 Jun 10;333(2):222-8 PMID: 23370224
  79. AID in somatic hypermutation and class switch recombination.
    Curr Opin Immunol. 2006 Apr;18(2):164-74 PMID: 16464563
  80. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
    J Clin Oncol. 2013 Feb 1;31(4):490-8 PMID: 23269987
  81. Comprehensive genomic characterization of squamous cell lung cancers.
    Nature. 2012 Sep 27;489(7417):519-25 PMID: 22960745
  82. CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.
    Immunity. 2016 Apr 19;44(4):913-923 PMID: 27096320
  83. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
    Can J Surg. 2001 Jun;44(3):180-8 PMID: 11407827
  84. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.
    Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44 PMID: 24484236
  85. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.
    Front Immunol. 2016 Oct 03;7:407 PMID: 27752258
  86. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    J Immunother. 2008 Jun;31(5):446-57 PMID: 18463540
  87. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.
    J Immunol. 2009 Sep 1;183(5):3195-203 PMID: 19667089
  88. Cancer Statistics, 2017.
    CA Cancer J Clin. 2017 Jan;67(1):7-30 PMID: 28055103
  89. Tertiary lymphoid organs in infection and autoimmunity.
    Trends Immunol. 2012 Jun;33(6):297-305 PMID: 22622061
  90. Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.
    Cancer Res. 2015 Sep 1;75(17):3456-65 PMID: 26183924
  91. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    J Thorac Oncol. 2017 Jun;12(6):943-953 PMID: 28341226
  92. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
    Cancer Res. 2007 Sep 1;67(17):8351-7 PMID: 17804751
  93. Tumor microenvironment is multifaceted.
    Cancer Metastasis Rev. 2011 Mar;30(1):13-25 PMID: 21271351
  94. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2016 Apr 10;34(11):1223-30 PMID: 26834066
  95. Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth.
    Anticancer Res. 2006 May-Jun;26(3A):1827-31 PMID: 16827114
  96. Shift in the IgG subclass distribution in patients with lung cancer.
    Lung Cancer. 1999 Apr;24(1):25-30 PMID: 10403691
  97. Message in a bottle from the tumor microenvironment: tumor-educated DCs instruct B cells to participate in immunosuppression.
    Cell Mol Immunol. 2017 Sep;14(9):730-732 PMID: 28757609
Article Info
Journal
Cellular & molecular immunology
Abbr.
Cell Mol Immunol
ISSN
2042-0226
DOI
10.1038/s41423-018-0027-x
Email
davidliuw@hotmail.com
lzhang@uhnresearch.ca
Published
2019-00-00
Epub
2018-00-08
Pages
6-18
Language
English
Region
China
NLM ID
101242872
PMCID
PMC6318290
Subset
IM
External Links
PubMed source DOI: 10.1038/s41423-018-0027-x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2